BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
46.58
-1.28 (-2.67%)
At close: 4:01PM EDT

47.18 +0.60 (1.29%)
Pre-Market: 6:47AM EDT

Stock chart is not supported by your current browser
Previous Close47.86
Open47.77
Bid46.83 x 2200
Ask47.01 x 800
Day's Range46.28 - 48.19
52 Week Range42.48 - 63.69
Volume16,321,221
Avg. Volume13,168,600
Market Cap76.194B
Beta (3Y Monthly)0.71
PE Ratio (TTM)12.27
EPS (TTM)3.80
Earnings DateOct 23, 2019 - Oct 28, 2019
Forward Dividend & Yield1.64 (3.43%)
Ex-Dividend Date2019-07-03
1y Target Est56.00
Trade prices are not sourced from all markets
  • PR Newswire

    Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

    THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ -- Amgen (AMGN) announced today that it has entered into an agreement with Celgene Corporation (CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.

  • Business Wire

    Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion

    Bristol-Myers Squibb Company (BMY) announced today that Celgene Corporation (CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (AMGN) under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash. Bristol-Myers Squibb previously announced the decision to divest OTEZLA in connection with the ongoing regulatory approval process for the Company’s pending merger with Celgene.

  • 3 Cancer Treatment Stocks to Buy Right Now
    Motley Fool

    3 Cancer Treatment Stocks to Buy Right Now

    Cancer is one of the toughest diseases to fight, and these companies are playing a great role in helping people combat it.

  • Better Buy: Biogen vs. Celgene
    Motley Fool

    Better Buy: Biogen vs. Celgene

    Which stock wins in a match-up between these two biotechs?

  • Why Is Bristol-Myers (BMY) Up 2.6% Since Last Earnings Report?
    Zacks

    Why Is Bristol-Myers (BMY) Up 2.6% Since Last Earnings Report?

    Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Will Lawsuits Sink Johnson & Johnson Stock?
    InvestorPlace

    Will Lawsuits Sink Johnson & Johnson Stock?

    Johnson & Johnson (NYSE:JNJ) stock is blue chip with a capital B. With its solid dividend and AAA credit rating, there's no denying that JNJ stock is high quality. But can the company's legal issues bring it to its knees?Source: Sundry Photography / Shutterstock.com The likely answer is no. While multi-billion dollar judgements sound scary, the company's sheer size may help insulate it from these issues. Let's take a closer look at JNJ, and see whether the risks outweigh opportunity with Johnson & Johnson stock. What's the Worst That Can Happen?As InvestorPlace contributor Josh Enomoto discussed Aug. 21, JNJ stock has two material legal risks. The first is the company's asbestos-contamination scandal. For decades, Johnson & Johnson allegedly kept quiet about the cancer risks of its baby powder products. Civil litigation has been going on for years. But only recently did federal authorities announce an investigation. Recent civil judgements were for $4.7 billion in July 2018, and $300 million in June 2019.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Retail Stocks to Buy on the Dip But JNJ's liability could be much less. As discussed in this Bloomberg article, most product liability judgements are reduced on appeal. But, as Enomoto discussed in his analysis, bad PR from the litigation could taint Johnson & Johnson stock. This scandal has been going on for years. While the story is well-known, it has not dominated the headlines.How about the Oklahoma opioid suit? After years of ignoring the opioid crisis, federal and state authorities are getting their act together. This puts opioid manufacturers in their cross-hairs, including JNJ. The Oklahoma suit alleges JNJ's Janssen Pharmaceuticals unit aggressively marketed opioids. Oklahoma is looking for $17 billion in damages, but JNJ could end up paying significantly less. Previous Oklahoma opioid suits ended with settlements. Purdue Pharma settled for $270 million. Teva Pharmaceuticals (NYSE:TEVA) settled for $85 million. This means that JNJ could avoid a multi-billion dollar judgement. But JNJ is likely not out of the woods just yet. Other states (or the Federal Government) could pursue action.Do these legal risks impact the valuation of JNJ stock? Let's see if shares are selling at a discount (or a premium) to its peers. JNJ Stock Trades at a Fair ValuationJohnson & Johnson currently trades at a forward price-to-earnings (forward P/E) ratio of 14.1. The company's Enterprise Value/EBITDA (EV/EBITDA) is currently 13. Here are the valuations of some of JNJ's competitors in the pharmaceutical space:Bristol-Myers Squibb (NYSE:BMY): Forward P/E of 10, EV/EBITDA of 9.8Eli Lilly (NYSE:LLY): Forward P/E of 16.5, EV/EBITDA of 15.7Merck (NYSE:MRK): Forward P/E of 15.6, EV/EBITDA of 14.1Pfizer (NYSE:PFE): Forward P/E of 15.9, EV/EBITDA of 10.1Based on this peers comparison, Johnson & Johnson stock appears fairly valued. On a forward P/E-basis, JNJ stock trades higher than BMY. On a EV/EBITDA basis, JNJ trades in the middle of the pack. It appears that the recent legal issues have barely impacted the JNJ stock price. Shares are down just about 12% from their 52-week high. It may take more to sink a stock with a $346.4 billion market cap.JNJ stock may be attractive to dividend investors. While the 2.91% yield is not particularly high, JNJ is a dividend aristocrat. The company has raised the dividend 57 years in a row. But investors should be cautious given the legal risks. While JNJ may be on the hook for much less than anticipated, it's tough to predict litigation outcomes. Not a Big Risk, But Not a Big OpportunityJohnson & Johnson will likely weather the litigation storm. The talcum powder judgement sound high, but the company could appeal and reduce the final amount. The Oklahoma opioid case also features an eye-popping number. Given the Purdue and Teva settlements, a multi-billion dollar verdict would be surprising.However, the stock offers limited upside. Shares appear fairly valued relative to peers. The company's dividend aristocrat status is a strong selling point. But for short-term plays, better opportunities lie elsewhere. If the legal issues result in a short-term hit to JNJ's stock price, investors may find opportunity. Keep Johnson & Johnson on your radar, and consider a position if the stock sees a material drop in price.As of this writing, Thomas Niel did not have a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy on the Dip * 7 Marijuana Stocks With Critical Levels to Watch * 7 Internet of Things Stocks to Buy Now The post Will Lawsuits Sink Johnson & Johnson Stock? appeared first on InvestorPlace.

  • 5 Healthcare Stocks to Buy for Healthy Dividends
    InvestorPlace

    5 Healthcare Stocks to Buy for Healthy Dividends

    These days, the healthcare stocks are looking pretty healthy compared to stocks in other spaces. Despite political pressures about lowering costs, "Medicare for All" and importing drugs, the sector has been riding high on a wave of optimism and growth. Demand for various healthcare solutions continues to rise as our aging population simply requires more. And that story is pretty much the same across the world.Even better is that recent market volatility has sent many investors into healthcare stocks for their high cash flows and strong dividend potential. Many healthcare stocks have long been dividend champions -- offering both high initial yields and overall strong dividend growth. For investors looking for income and the ability to keep that income rising over the long haul, healthcare stocks can't be beaten.The best part is that the sector's overall growth rates don't seem to be slowing anytime soon. That makes healthcare a prime destination for long-term investors.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Own Through a Global Recession So, which healthcare stocks have great growth trajectories and can pay you plenty of dividends for the long-term? Here's a prescription for five that fit the bill. Healthcare Stocks to Buy Today: Baxter International Inc (BAX)Source: Shutterstock Dividend Yield: 1.1%If you've ever been in the hospital, there's a good chance that you've used products made by Baxter International (NYSE:BAX). That bag of Ringer's solution connected to your I.V. is one of its most famous products. However, Baxter's catalog spans not only all the stuff needed for running intravenous drugs, including the tubing, pumps and connectors, but also a variety of premixed drugs and therapies as well.Those bags of basic Ringer's solution, tubes, and other hospital must-haves create plenty of repeat orders from facility administrators. You can't really operate a hospital without them. As a result, BAX ships more than one million sterile units each day.This niche has served BAX well over the years and has made it a profit machine. Last quarter, Baxter saw a 4% jump to its operational revenues and managed to see an adjusted profit gain of 16% year-over-year. This follows great results for the first quarter of 2019 and the fourth quarter of last year. These wins plus its recent top-notch results allowed management to boost its full-year 2019 earnings guidance.And there's a good chance that it'll beat even those better numbers. BAX has several new approved products hitting the market this year, including the only intravenous insulin product Myxredlin and new nutritional products. Meanwhile, Baxter is poised to see growth from increased home dialysis patients.With strong revenues already in the tank and future growth on the horizon, BAX should be able to keep growing its dividend as well. While it only yields 1.1% today, that payout has increased by 156% over the last 10 years. Bristol-Myers Squibb (BMY)Source: Shutterstock Dividend Yield: 3.43%The major pharmaceuticals are some of the best healthcare stocks to comb for dividends and Bristol-Myers Squibb (NYSE:BMY) could be one of the best. The firm has a huge portfolio of drugs, including many blockbusters than produce ample amounts of cash flow. That plus its 3.43% yield is worth the price of admission alone. However, the real reason to buy BMY is its status as a major cancer fighter.That title comes from blockbuster cancer drug Opdivo. The oncology medicine pulls in more than $2 billion in quarterly revenues for the firm and continues to see growth. Last quarter, sales of Opdivo managed to grow by 12%. Meanwhile, Bristol-Meyers continues to pivot the success of Opdivo in other directions as well. And we can't forget the other cancer fighters under its umbrella -- such as Yervoy -- which also grew by double digits.The best part is BMY is going to need a bigger oncology umbrella. That's because of its pending buyout of Celgene (NASDAQ:CELG). CELG's portfolio and pipeline of cancer drugs will fit perfectly with BMY's. While the integration and antitrust issues are taken a bit longer than expected, the deal is moving forward and when it's finally done, Bristol Meyers will have one of the best overall cancer portfolios around. This should lead to plenty of growth down the road. Especially when considering that the government may have little ability to regulate them. * 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar For income seekers, this could make BMY a top healthcare stock to buy for years' worth of dividend growth. Physicians Realty Trust (DOC)Source: Shutterstock Dividend Yield: 5.3%It's not just the drugs or equipment in a hospital that can pay some hefty dividends. The owners of the hospital itself could be the real income play. And that makes Physicians Realty Trust (NYSE:DOC) one of the best sleepier healthcare stocks to buy.DOC is a real estate investment trust (REIT) that owns 250 properties across 30 different states. The bulk of these -- around 93% of its total portfolio -- are medical office buildings. Medical office buildings are one of the more stable varieties of medical properties as they are generally constructed for this purpose only. Secondly, most of DOC's properties are signed to long-term leases and are located on major health campuses that are affiliated with leading health systems. This provides a very stable base of rental income for the REIT's bottom line.Even better is that 78% of DOC's portfolio is triple-net leased. This holy grail of leases means that tenants are responsible for paying items like taxes, maintenance and insurance costs. This provides better margins and cash flows for DOC's buildings. Those cash flows have been growing. since its IPO in 2013, DOC's FFO has grown by a staggering 195%. And while that torrid growth has slowed a bit in recent years, the healthcare stock still pumps out plenty of cash to fund its steady dividend. Moreover, DOC continues to use its strong balance sheet to perform smart M&A transactions to boost its portfolio further.In the end, Physicians Realty Trust is a great healthcare stock to add some yield to your portfolio. Cardinal Health (CAH)Source: Shutterstock Dividend Yield: 4.42%Truth be told, Cardinal Health (NYSE:CAH) has a few warts and isn't a pristine member of the best healthcare stocks club. The firm's two main lines of business -- drug distribution and medical devices -- aren't doing so hot right now. For one thing, the distributors are being taken down as they are the main targets of lower-price political punditry, while the kinds of devices it makes are directly in the line of fire from Medicare for All plans. Add in pending opioid legislation and Cardinal has been hit hard. Shares of CAH are around 23% lower from their peaks this year.But the drop has pushed shares into bargain territory. Today, CAH can be had for a P/E of under 10 and a dividend yield of 4.42%. That's dirt cheap, especially considering that its situation may not be that bad.For one thing, CAH is expected to see steady growth. As one of the space's largest distributors of drugs, including low-price generics, the firm has an entrenched position among hospitals and doctors. Cardinal did see its full-year revenues increase by 6% to a whopping $145.5 billion for fiscal 2019. And that leadership position throws off a lot of cash. Adding its low debt compared to peers and CAH has plenty of wiggle room to navigate the challenges, with a payout ratio of just 40%. Right now, it's priced as it won't be able to survive. That's just ridiculous. * 7 "Boring" Stocks With Exciting Prospects While it may seem like a risky play, CAH is priced cheap enough and it has a strong enough yield that it's worth the gamble. Becton Dickinson (BDX)Source: Shutterstock Dividend Yield: 1.25%On the surface, Becton Dickinson (NYSE:BDX) looks like one of the most boring healthcare stocks. That's because the firm is one of the largest producers of so-called sharps products. We're talking needles and syringes.BDX's product catalog spans everything from insulin needles and catheters to more advanced regional anesthesia and drug delivery products. The real win for Becton is that these items are one-time only products. Just like Baxter, hospitals and doctors have to keep calling their BDX sales rep for more. This niche produces ample cash flow and its integration of rival Bard only boosted its catalog further.But BDX isn't simply staying in its lane. In recent years, it has expanded its portfolio into some high-tech devices. This includes intravenous pumps, surgery products and even PCR/life science equipment. These divisions have been growing nicely and are starting to contribute significantly to Becton's bottom line.The best part is that BDX's ample cash flows are allowing it to pay down the debt it took out to buy Bard faster than expected. Management expects to use that future cash flows to fund tuck-in acquisitions, conduct buybacks and boost its dividend further. Already, BDX has grown its payout by 42% over the last five years.Given its steady revenues and future potential, BDX makes an ideal dividend growth play among the healthcare stocks.At the time of this writing, Aaron Levitt did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy on the Dip * 7 Marijuana Stocks With Critical Levels to Watch * 7 Internet of Things Stocks to Buy Now The post 5 Healthcare Stocks to Buy for Healthy Dividends appeared first on InvestorPlace.

  • Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer
    Zacks

    Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer

    Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.

  • Retrophin Down on Neurological Disorder Drug Study Failure
    Zacks

    Retrophin Down on Neurological Disorder Drug Study Failure

    Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.

  • The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon
    Zacks

    The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon

    The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon

  • Top Stock Reports for Home Depot, Abbott & Bristol-Myers
    Zacks

    Top Stock Reports for Home Depot, Abbott & Bristol-Myers

    Top Stock Reports for Home Depot, Abbott & Bristol-Myers

  • The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer
    Zacks

    The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer

    The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer

  • The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes
    Zacks

    The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes

    The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes

  • AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study
    Zacks

    AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study

    AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.

  • Disney Whistleblower's Time in the Sun
    Zacks

    Disney Whistleblower's Time in the Sun

    Former Disney employee Sandra Kuba says company executives have been overstating revenues.

  • BMY Stock Plus Celgene Will Be A Top 5 Pharma — But Should You Buy It?
    Investor's Business Daily

    BMY Stock Plus Celgene Will Be A Top 5 Pharma — But Should You Buy It?

    Pharmaceutical company Bristol-Myers has been in a downtrend since 2016 and after unveiling its merger with Celgene. Is now the right time to buy BMY stock?

  • Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales
    Zacks

    Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales

    Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.

  • Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio
    Zacks

    Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.

  • 4 High Earnings Yield Stocks to Bolster Your Portfolio
    Zacks

    4 High Earnings Yield Stocks to Bolster Your Portfolio

    Earnings yield is quite effective for determining undervalued stocks.

  • New Strong Buy Stocks for August 20th
    Zacks

    New Strong Buy Stocks for August 20th

    New Strong Buy Stocks for August 20th

  • Recession Fears Ebb on Fresh Wave of Stimulus: 5 Top Gainers
    Zacks

    Recession Fears Ebb on Fresh Wave of Stimulus: 5 Top Gainers

    Fears of recession ebb after White House considers tax cuts for millions of workers, China unveils new interest rate reforms and Germany hints at stimulus measures.

  • Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
    Zacks

    Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer

    Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.

  • Barrons.com

    Market Volatility Got You Nervous? The Merger Fund Might Be the Answer

    The Merger Fund’s strategy of assessing what mergers are likely to go through and when works well in times of market volatility. It’s turned in positive returns for 27 out of the past 30 years.

  • Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
    Zacks

    Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC

    Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.